Pearl IRB,LLC and Trafalgar Ethics Board, Inc. announce a partnership to provide one stop shop service for central IRB (Institutional Review Board) services for clients. The trend for research sponsors to conduct multi-center global clinical trials continues to grow, with the United States and Canada accounting for 60.5%1 of sponsored clinical trials in 2010. Pearl IRB, based in the United States in Indianapolis and Trafalgar Ethics Board headquartered in the Toronto area in Canada, join forces to deliver integrated United States–Canada study reviews.
“We have partnered to serve the needs of our clients in a more streamlined fashion,” shares Ali Thompson, Director of Trafalgar Ethics Board. “Both our Canadian clients and US based sponsors are demanding higher quality and increased efficiencies in the global regulatory oversight of their clinical trials. By working together to provide United States–Canada IRB reviews, we eliminate much duplication and help streamline work for our clients.”
Clinical trials are often delayed for many reasons including contract negotiations, budgeting issues, and IRB reviews. “We strive to decrease site review times by integrating our processes to provide parallel US and Canadian site reviews, states Diana Caldwell, President and CEO of Pearl IRB. “Additionally, we will partner to offer additional services that are of high value to our clients including medical writing, GCP/ICH assistance, and site training all of which reach across Canada and the US now.”
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.